Bucladesine sodium salt
Bucladesine sodium is a cardiac stimulant. (In Vitro) :Both choline acetyltransferase (ChAT) and vesicular acetylcholine transporter (VAChT) mRNA increased approximately fourfold after treatment of PC12 cells with Bucladesine (dibutyryl cyclic AMP; dbcAMP) . ChAT and PKA activity are also increased by Bucladesine. (In Vivo) :Intrahippocampal infusion of Bucladesine into the CA1 region (male Albino-Wistar rats) can cause an improvement in spatial memory in maze task. Bilateral infusion of 10 μM and 100 μM Bucladesine leads to a significant reduction in escape latency and travel distance (showing an improvement in spatial memory) . Bucladesine via activation of PKA and induction of cAMP/PKA pathway improved spatial memory retention.
Product Specifications
CAS Number
16980-89-5
Product Name Alternative
Bucladesine sodium | DbcAMP sodium
Field of Research
Pharmacology & Drug Discovery
Purity
>98% (HPLC)
Solubility
DMSO : 150 mg/mL 305.27 mM; H2O : ≥ 42 mg/mL 85.48 mM
Smiles
CCCC (=O) NC1=NC=NC2=C1N=CN2C3C (C4C (O3) COP (=O) (O4) [O-]) OC (=O) CCC.[Na+]
Molecular Formula
C18H23N5NaO8P
Molecular Weight
491.37
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
Sodium (4aR,6R,7R,7aR) -6- (6-butyramido-9H-purin-9-yl) -7- (butyryloxy) tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-2-olate 2-oxide
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Major Vault Protein (MVP) (1032), CF568 conjugate, 0.1mg/mL
CD45RO (UCHL-1), CF640R conjugate, 0.1mg/mL
TGF-beta (1D11.16.8), CF640R conjugate, 0.1mg/mL
